This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Alzprotect, Ellipses Pharma Limited, Institute of Cancer Research: Royal Cancer Hospital (the). Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 6 
1 out of 6 
1 out of 13 Years Active: 2026
Title: Jonathan Loughrey: Pharmaceutical Patent Inventor.
Introduction
Jonathan Loughrey is an inventor associated with pharmaceutical research and patent activity. The information provided identifies him as based in Midlothian, Great Britain, and credits him with 1 patent.
Latest Patents
His listed patent, “Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine,” concerns salts and polymorphic forms of Compound A. The compound inhibits Aurora kinase and FMS-like tyrosine kinase 3 (FLT3) activity.
The invention also describes methods for preparing the salts and polymorphic forms, pharmaceutical compositions containing them, and potential uses in treating proliferative disorders such as cancer. It further addresses diseases and conditions in which Aurora kinase or FLT3 activity is implicated.
Career Highlights
Loughrey’s listed professional affiliations include Ellipses Pharma Limited and the Institute of Cancer Research: Royal Cancer Hospital. These affiliations place his recorded work in the context of pharmaceutical and cancer research.
Collaborations
His listed coworkers include Natalie Kelk and Michaela Kreiner. Their names are associated with the professional and patent context provided for Loughrey.
Conclusion
Jonathan Loughrey’s recorded patent work focuses on pharmaceutical forms and potential therapeutic applications of a compound targeting Aurora kinase and FLT3 activity.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile